sublicensees

You grant Amazon.com and its affiliates and sublicensees the right to use the name that you submit in connection with such content, if they choose.

Well, Ladies. Shall We Hack the Crowd? fusenumber8 2007

In addition, Salix may pay sales-based milestones of as much as $200 million plus royalties from U.S. sales, as well as 60 percent of all revenue received from non-U.S. sublicensees.

unknown title 2011

Salix also will pay sales-based milestones of up to $200 million plus royalties on product sales in the U.S., as well as 60% of all revenue received from non-U.S. sublicensees.

unknown title 2011

For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing.

unknown title 2011

For Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing.

unknown title 2011

Salix also will pay sales-based milestones of up to $200 million plus royalties on product sales in the U.S., as well as 60% of all revenue received from non-U.S. sublicensees.

unknown title 2011

The Boston Globe, Boston Metro, and their sublicensees permission to publicly display, reproduce, and use the photos in any form or media for any and all editorial and related promotional purposes.

Boston.com Top Stories 2010

For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; BioSante's need for and ability to obtain additional financing; the effect of general business and economic conditions; and risks arising from BioSante's merger with Cell Genesys.

The Earth Times Online Newspaper 2010

Rexahn, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of Rexahn's licensees or sublicensees; the success of clinical testing; and Rexahn's need for and ability to obtain additional financing.

The Earth Times Online Newspaper 2010

Curis is eligible to receive cash payments upon the successful achievement of specified clinical development and regulatory approval milestones, as well as royalties upon commercialization of GDC-0449 by Genentech and its sublicensees.

Medlogs - Recent stories 2010